Expression of apolipoprotein E inhibits aggregation of the C-terminal fragments of μ-amyloid precursor protein

doi:10.1016/0304-3940(96)12663-X

Neuroscience Letters

Volume 210, Issue 1, 24 May 1996, Pages 65-68

https://doi.org/10.1016/0304-3940(96)12663-X Get rights and content

Abstract

An important role of apolipoprotein E in the amyloidogenesis of Alzheimer's disease is suggested by an accumulation of apolipoprotein E in β-amyloid plaques and a genetic association between Alzheimer's disease and one of the allelic variants (APOE4) of apolipoprotein E. Overexpression of a C-terminal region of β-amyloid precursor protein brings about aggregation of the C-terminal fragments in COS cells. This COS cell culture system was used to study effects of apolipoprotein E on aggregation of the C-terminal fragments. When both apolipoprotein E and the C-terminal fragments were overexpressed in COS cells, Western blot analyses revealed significant inhibition of aggregation of the C-terminal fragments. No significant differences between apolipoprotein E3 and E4 in the inhibitory activities were found by this method. Apolipoprotein E may inhibit formation of amyloid fibrils.

References (22)

K. Fukuchi et al.
Overexpression of amyloid precursor protein alters its normal processing and is associated with neurotoxicity
Biochem. Biophys. Res. Commun.
(1992)
K. Fukuchi et al.
Expression of a carboxyterminal region of the, β-amyloid precursor protein in a heteroge neous culture of neuroblastoma cells: evidence for altered processing and selective neurotoxicity
Mol. Brain Res.
(1992)
M.J. LaDu et al.
Isoform-specific binding of Apolipoprotein E to β-amyloid
J. Biol. Chem.
(1994)
B. Mazur-Kolecka et al.
Apolipoprotein E3 and E4 induce, and transthyretin prevents accumulation of the Alzheimer's β-amyloid peptide in cultured vascular smooth muscle cells
Brain Res.
(1995)
Y. Namba et al.
Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease
Brain Res.
(1991)
J. Näslund et al.
Characterization of stable complexes involv ing apolipoprotein E and the amyloid β peptide in Alzheimer's disease brain
Neuron
(1995)
C.J. Pike et al.
Amino-terminal deletions enhance aggregation of β-amyloid peptides in vitro
J. Biol. Chem.
(1995)
A.M. Saunders et al.
Apolipoprotein E E4 allele distribution in late onset Alzheimer's disease and in other amyloid forming diseases
Lancet
(1993)
K.H. Weisgraber et al.
Identification of the disulfidelinked homodimer of apolipoprotein E3 in plasma: impact on receptor binding activity
J. Biol. Chem.
(1991)
N.T.J. Bailey
Statistical Methods in Biology

E.H. Corder et al.

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

Science

(1993)

Cited by (7)

Inhibition of amyloid formation: A strategy to delay the onset of Alzheimer's disease
1997, Current Opinion in Chemical Biology
Apolipoprotein E and Alzheimer's disease: A review of recent studies
1997, Pharmacology Biochemistry and Behavior
There are three isoforms of the 33-kDa protein apolipoprotein E (apoE), termed apoE2, apoE3, and apoE4, each encoded by distinct genes APOE2, APOE3, and APOE4, respectively. In 1993, the APOE genotype was identified as a risk factor for Alzheimer's disease (AD) and was subsequently acknowledged to account for approximately 60% of all cases. The influence of the APOE genotype in AD is clearly isoform dependent, APOE4 imparting susceptibility and APOE2 protection. Thus, patients homozygous for the E4 allele show a very strong likelihood of developing the disease by age 75, whereas patients carrying at least one E2 allele are unlikely to develop symptoms of AD by this age. A major issue in AD research is therefore to understand the functional differences between the ApoE isoforms, with the ultimate aim of designing the next generation of drugs to treat this disease. The purpose of the present article is to summarise some of this work. This review encompasses the rapidly developing molecular, cellular, and behavioural research into ApoE, and attempts to highlight those findings we consider to be of particular significance.
Candidate SNP markers of familial and sporadic Alzheimer's diseases are predicted by a significant change in the affinity of TATA-binding protein for human gene promoters
2017, Frontiers in Aging Neuroscience
Disrupting β-amyloid aggregation for Alzheimer disease treatment
2007, Current Topics in Medicinal Chemistry
Accumulation of amyloid-β protein in exocrine glands of transgenic mice overexpressing a carboxyl terminal portion of amyloid protein precursor
2000, International Journal of Experimental Pathology
Perlecan binds to the β-amyloid proteins (aβ) of Alzheimer's disease, accelerates aβ fibril formation, and maintains aβ fibril stability
1997, Journal of Neurochemistry

View all citing articles on Scopus

^☆: This work was supported in part by the National Institute of Health grants AG12850, AG05136, RR11105, and Alzheimer's Association/ Mervin D. Peck Investigator-Initiated Research Grant.

¹: We thank J. Miyazaki for providing the pCAGGS expression vector, L. Chan for apoE3 cDNA, and H. Wisniewski for antibody 6E10.

View full text

Expression of apolipoprotein E inhibits aggregation of the C-terminal fragments of μ-amyloid precursor protein☆

Abstract

Biochem. Biophys. Res. Commun.

Mol. Brain Res.

J. Biol. Chem.

Brain Res.

Brain Res.

Neuron

J. Biol. Chem.

Lancet

J. Biol. Chem.

Statistical Methods in Biology

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

Science